Dr. Merritt’s research interests are to investigate and innovate in the realm of translating experimental therapies for clinical use. He is currently part of the development project to investigate gene editing therapies for non-small cell lung carcinoma and other solid tumors, with a goal to initiate first-in-human clinical trials utilizing these cutting-edge approaches. Dr. Merritt provides a unique clinical perspective to augment the investigational research performed at the Gene Editing Institute, aiding in the transition from bench to bedside.
